Trial Profile
A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-052
- Sponsors Merck Sharp & Dohme
- 24 Oct 2023 Results of post hoc pooled analysis (n=49) assessing the efficacy and safety outcomes with pembrolizumab rechallenge for patients with advanced/metastatic urothelial cancer from KEYNOTE-045, KEYNOTE-052 and KEYNOTE-361 trials, presented at the 48th European Society for Medical Oncology Congress.
- 11 Sep 2023 Result of pooled analysis from KEYNOTE-001,KEYNOTE-059, KEYNOTE-048, KEYNOTE-427, KEYNOTE-052, KEYNOTE-361 assessing Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression published in the Cancer Cell
- 06 Dec 2022 Results assessing efficacy and safety (after up to 5 years of follow-up) of pembrolizumab in metastatic urothelial carcinoma from KEYNOTE-045 and KEYNOTE-052 studies, published in the Annals of Oncology.